საკვანძო სიტყვები
multidrug-resistant TB (MDR-TB)/rifampicin-resistant TB (RR-TB)
treatment outcomes
Georgia (National Center for Tuberculosis and Lung Diseases)
bedaquilline
delaminid
levofloxacin
extrapulmonary tuberculosis
HIV co-infection
comorbidities
როგორ უნდა ციტირება
ანოტაცია
Background:
Treating drug-resistant tuberculosis was particularly complex for patients who also have comorbid conditions or extrapulmonary tuberculosis.
Aim:
The study's objective is to investigate the impact of various demographics, clinical variables, and treatment regimens on treatment outcomes in patients with drug-resistant tuberculosis.
Methods:
A retrospective cohort study based on data collected from 595 DR-TB patients aged ≥15 years treated at the NCTLD in Tbilisi, Georgia, from 2019 to 2021. Inclusion criteria involved patients with microbiologically verified DR-TB who had complete treatment outcome records. Patients under the age of 15 or without verified treatment outcomes were excluded from the study.
Results:
Successful treatment outcomes were seen in new TB cases, those without the extra-pulmonary TB, and those without Delamanid included in their treatment. A positive association was also established with the administration of Levofloxacin and Bedaquiline.
Conclusion:
Improved treatment outcomes were noted in newly diagnosed pulmonary TB patients who did not undergo treatment with Delamanid. These findings highlight the importance of early diagnosis and the careful tailoring of treatment strategies to address drug-resistant tuberculosis (DR-TB) effectively.
წყაროები
World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
Gegia M, et al. History and impact of TB control in Georgia. Public Health Action. 2014;4(Suppl 2):S22–S28.
Tukvadze N, et al. Multidrug-Resistant Tuberculosis and Risk Factors in Georgia. Int J Tuberc Lung Dis. 2012.
National Center for TB and Lung Diseases (NCTLD). Annual TB Report, Georgia, 2021.
TB DIAH. Center of Excellence for TB Monitoring and Evaluation. https://www.tbdiah.org/center-of-excellence/
Swiss TPH. MDR-TB in Georgian Prisons. https://www.swisstph.ch/en/news/news-detail/news/prisons-accelerate-spread-of-multidrug-resistant-tuberculosis-in-georgia/
https://publications.ersnet.org/content/erj/56/suppl64/460#abstract
European Respiratory Journal 2020 56(suppl 64): 460; DOI: https://doi.org/10.1183/13993003.congress-2020.460
World Health Organization. (2023). Global Tuberculosis Report 2023. https://doi.org/10.256/WHO/2023
Migliori, G. B., et al. (2022). Treatment outcomes of multidrug-resistant TB in the Caucasus region. Int J Tuberc Lung Dis, 26(5), 456-464. https://doi.org/10.5588/ijtld.21.0185
Kumar, A., et al. (2021). Delamanid-associated treatment failure: pharmacokinetic and resistance insights. Lancet Infect Dis, 21(9), e312-e321. https://doi.org/10
Zhang, Y., & Wang, L. (2020). Impact of DOTS implementation on DR-TB outcomes in Eastern Europe. BMC Public Health, 20, 1123. https://doi.org/10.1186/s12889-020-09544-5